Since E2814 is designed to target pathologic tau and can attenuate aggregated tau spreading in preclinical experiments [237], and lecanemab, an anti-Aβ antibody approved through the FDA accelerated approved process for AD treatment, can reduce the brain amyloid and slow the rate of cognitive decline in patients with early AD [10]. The gene discussed is MAPT; the disease is Mental deterioration.